CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.511
EU - Europa 7.798
AS - Asia 6.542
SA - Sud America 1.097
AF - Africa 151
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 22
Totale 38.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.318
GB - Regno Unito 2.597
SG - Singapore 2.115
CN - Cina 1.694
IT - Italia 1.198
HK - Hong Kong 1.161
BR - Brasile 913
DE - Germania 753
SE - Svezia 695
IE - Irlanda 434
VN - Vietnam 424
UA - Ucraina 415
RU - Federazione Russa 363
PL - Polonia 357
TR - Turchia 347
FI - Finlandia 267
FR - Francia 212
BG - Bulgaria 189
ID - Indonesia 179
IN - India 169
CA - Canada 111
JP - Giappone 96
AR - Argentina 67
IQ - Iraq 61
MX - Messico 48
NL - Olanda 47
BD - Bangladesh 44
ES - Italia 40
BE - Belgio 39
LT - Lituania 39
EC - Ecuador 33
EG - Egitto 33
KR - Corea 33
AT - Austria 31
MY - Malesia 31
ZA - Sudafrica 30
PK - Pakistan 25
VE - Venezuela 25
MA - Marocco 23
TW - Taiwan 23
AU - Australia 21
RO - Romania 19
EU - Europa 17
IR - Iran 17
CL - Cile 16
TN - Tunisia 15
UZ - Uzbekistan 15
CH - Svizzera 14
CO - Colombia 14
CZ - Repubblica Ceca 14
MD - Moldavia 14
SA - Arabia Saudita 13
IL - Israele 11
PY - Paraguay 11
KE - Kenya 10
DO - Repubblica Dominicana 9
JO - Giordania 9
PE - Perù 9
NO - Norvegia 8
NP - Nepal 8
PH - Filippine 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
KZ - Kazakistan 7
NZ - Nuova Zelanda 7
SN - Senegal 7
AZ - Azerbaigian 6
GH - Ghana 6
HU - Ungheria 6
UY - Uruguay 6
DZ - Algeria 5
MT - Malta 5
PS - Palestinian Territory 5
A2 - ???statistics.table.value.countryCode.A2??? 4
ET - Etiopia 4
GR - Grecia 4
JM - Giamaica 4
LU - Lussemburgo 4
OM - Oman 4
PA - Panama 4
QA - Qatar 4
TT - Trinidad e Tobago 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BO - Bolivia 3
BZ - Belize 3
CG - Congo 3
HN - Honduras 3
IS - Islanda 3
LB - Libano 3
LK - Sri Lanka 3
MK - Macedonia 3
MN - Mongolia 3
SK - Slovacchia (Repubblica Slovacca) 3
BH - Bahrain 2
BW - Botswana 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
Totale 38.111
Salva come PNG Salva come JPEG
Città #
Fairfield 3.260
Ashburn 1.984
Woodbridge 1.816
Santa Clara 1.811
Southend 1.682
Houston 1.465
Singapore 1.314
Seattle 1.281
Chandler 1.195
Hong Kong 1.151
Cambridge 1.028
Wilmington 1.017
Jacksonville 744
Ann Arbor 736
Dearborn 736
London 490
Nyköping 473
Beijing 460
Dublin 429
Warsaw 347
Modena 310
San Diego 243
Dallas 232
Izmir 219
New York 215
Los Angeles 208
Princeton 188
Sofia 188
Eugene 174
Council Bluffs 169
Jakarta 157
The Dalles 142
Chicago 136
Hefei 132
Helsinki 129
Moscow 115
Shanghai 115
Dong Ket 103
Buffalo 99
Ho Chi Minh City 99
Falls Church 85
Columbus 83
Hanoi 81
Munich 77
São Paulo 77
Milan 73
Boardman 64
Tokyo 64
Bremen 63
Fremont 63
Phoenix 56
Redwood City 56
Salt Lake City 55
Frankfurt am Main 49
Ottawa 47
Guangzhou 46
Redondo Beach 39
Baghdad 37
San Jose 37
San Giuliano Milanese 36
Bologna 35
Brussels 35
Lauterbourg 34
Orem 32
Brooklyn 31
Rome 30
Atlanta 29
Norwalk 29
Poplar 29
Belo Horizonte 28
Rio de Janeiro 28
Mumbai 27
Seoul 25
Turku 25
Denver 24
Nuremberg 23
Tampa 23
Toronto 23
Lawrence 22
Asyut 21
Düsseldorf 21
Brasília 20
Chennai 20
Kilburn 20
Nanjing 19
Chiswick 18
Jinan 18
Paris 18
Portsmouth 18
Florence 17
Kunming 17
Montreal 17
Curitiba 16
Des Moines 16
Mexico City 16
Hangzhou 15
Stockholm 15
Banqiao 14
Boston 14
Campinas 14
Totale 28.876
Salva come PNG Salva come JPEG
Nome #
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 553
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 520
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 383
GD2 expression in breast cancer. 380
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 354
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 352
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 333
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 323
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 320
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 318
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 315
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 313
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 298
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 291
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 286
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 284
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 284
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 282
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 280
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 278
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 277
5-Fluorouracil pharmacogenomics: still rocking after all these years? 274
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 272
Transient sunitinib resistance in gastrointestinal stromal tumors. 269
Il trattamento di prima e seconda linea nel carcinoma gastrico 269
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 269
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 268
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 263
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 262
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 261
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 261
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 261
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 260
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 260
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 254
The evolving role of microsatellite instability in colorectal cancer: A review 252
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 249
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 249
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 247
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 246
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 243
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 240
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 238
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 236
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 235
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 235
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 235
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 234
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 234
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 232
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 231
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 230
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 227
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 226
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 226
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 226
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 225
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 224
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 222
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 222
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 221
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 220
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 220
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 219
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 219
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 216
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 215
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 213
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 213
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 211
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 211
Male mammary myofibroblastoma: Two case reports and brief review of literature 211
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 210
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 207
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 206
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 206
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 205
The Italian Rare Pancreatic Exocrine Cancer Initiative 205
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 203
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 203
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 202
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 202
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 202
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 201
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 200
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 199
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 199
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 199
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 198
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 197
Bone metastases- Pharmacological treatment 195
Selecting the best treatment for an individual patient. 195
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 195
Progress of molecular targeted therapies for advanced renal cell carcinoma. 194
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 194
Reply to O. Corli et al and M. Lucchesi et al 194
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 193
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 193
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 192
Totale 24.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.935
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.177 0 0 0 0 0 469 420 647 307 567 376 391
2021/20223.569 237 431 328 152 98 248 184 192 381 351 654 313
2022/20233.576 418 361 223 319 411 422 54 283 771 44 150 120
2023/20242.059 77 117 116 194 425 121 256 350 43 54 95 211
2024/20256.909 276 93 122 463 1.458 1.051 494 463 835 404 420 830
2025/20265.449 687 279 885 1.105 1.564 929 0 0 0 0 0 0
Totale 38.497